Advertisement

Topics

Rituximab Plus Lenalidomide More Effective Against Indolent Lymphoma Than Rituximab Alone

12:30 EDT 16 May 2019 | Weill Cornell Medical College

The addition of an oral immunomodulatory drug to a commonly employed antibody therapy is more effective against chronic, indolent lymphoma than the antibody alone, according to the results of a Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Original Article: Rituximab Plus Lenalidomide More Effective Against Indolent Lymphoma Than Rituximab Alone

NEXT ARTICLE

More From BioPortfolio on "Rituximab Plus Lenalidomide More Effective Against Indolent Lymphoma Than Rituximab Alone"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...